Tag: Human Simplex Virus (HSV 2)
A revolution in nanotech helps create a new vaccine delivery system that could literally...
The Nanopatch, a revolutionary new needle-free device for delivering vaccines, has won a $15 million capital injection (pun intended), but also was an award winner at World Vaccine Congress. After eight years of research, the Nanopatch looks set to revolutionise vaccination delivery forever.
Queensland biotech startup Vaxxas gets $15 million from venture funds
Vaxxas Pty. Ltd. has won a $15 million investment from venture groups led by OneVentures. Other investors include Brandon Capital Partners, the Medical Research Commercialisation Fund and U.S.-based HealthCare Ventures. Vaxxas is the first Queensland company to be funded under the Bio Capital Fund, which has swelled to nearly $250 million, established last year with the help of Health Care Ventures and Eli Lilly, among others. The investment was negotiated in the main by UniQuest Pty Limited, the University of Queensland’s main commercialisation company.
